Antimicrobial peptide resistance in Neisseria meningitidis

Yih-Ling Tzeng, Emory University
David Stephens, Emory University

Journal Title: Biochimica et Biophysica Acta - Biomembranes
Volume: Volume 1848, Number 11
Publisher: Elsevier | 2015-11-01, Pages 3026-3031
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.bbamem.2015.05.006
Permanent URL: https://pid.emory.edu/ark:/25593/rtj16

Final published version: http://dx.doi.org/10.1016/j.bbamem.2015.05.006

Copyright information:
© 2015 Elsevier B.V.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed April 11, 2019 7:13 PM EDT
Antimicrobial peptide resistance in *Neisseria meningitidis*

Yih-Ling Tzeng\(^a\) and David S. Stephens\(^{a,b,*}\)

\(^a\)Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA

\(^b\)Laboratories of Microbial Pathogenesis, Medical Research Service, Veterans Affairs Medical Center, Decatur, GA 30033, USA

Abstract

Antimicrobial peptides (AMPs) play an important role as a host defense against microbial pathogens and are key components of the human innate immune response. *Neisseria meningitidis* frequently colonizes the human nasopharynx as a commensal but also is a worldwide cause of epidemic meningitis and rapidly fatal sepsis. In the human respiratory tract, the only known reservoir of *N. meningitidis*, meningococci are exposed to human endogenous AMPs. Thus, it is not surprising that meningococci have evolved effective mechanisms to confer intrinsic and high levels of resistance to the action of AMPs. This article reviews the current knowledge about AMP resistance mechanisms employed by *N. meningitidis*. Two major resistance mechanisms employed by meningococci are the constitutive modification of the lipid A head groups of lipooligosaccharides by phosphoethanolamine and the active efflux pump mediated excretion of AMPs. Other factors influencing AMP resistance, such as the major porin PorB, the pilin biogenesis apparatus, and capsular polysaccharides, have also been identified. Even with an inherently high intrinsic resistance, several AMP resistance determinants can be further induced upon exposure to AMPs. Many well-characterized AMP resistance mechanisms in other Gram-negative bacteria are not found in meningococci. Thus, *N. meningitidis* utilizes a limited but highly effective set of molecular mechanisms to mediate antimicrobial peptide resistance.

Graphical abstract
1. Introduction

*Neisseria meningitidis*, the meningococcus, is a Gram negative aerobic encapsulated diplococcal β-proteobacterium. Meningococci are carried asymptotically by 5 to 10% of the overall population in non-epidemic periods and are transmitted from a carrier by aerosol droplets or respiratory secretions. *N. meningitidis* is unique among the major bacterial agents of meningitis in that it causes epidemic as well as endemic (sporadic) disease. Approximately 500,000 cases of invasive meningococcal disease have occurred annually worldwide, with at least 50,000 deaths and as many survivors suffering neurological sequelae [1]. The meningococcus causes a range of disease: rapid onset meningitis and severe sepsis (meningococcemia), septic arthritis, pneumonia, purulent pericarditis, conjunctivitis, otitis, sinusitis, and urethritis. Meningococci are classified by serologic typing based on the biochemical composition of the capsular polysaccharides (serogroup), major outer membrane porin proteins (serotype), other outer membrane proteins (serosubtype), and lipooligosaccharide (immunotype). Of the 12 serogroups identified, almost all of invasive cases are caused by meningococci that express one of six capsular polysaccharides (serogroups A, B, C, X, Y, and W) and most epidemic and endemic cases of meningococcal disease are caused by a limited number of clonal groups defined genetically using multilocus sequence typing (MLST). The US licensed vaccines against *N. meningitidis* are based on capsular polysaccharides (CPS) with the more recent development of CPS-protein conjugate vaccines for different combinations of serogroups A, C, Y and W [2-5]. New serogroup B vaccines using sub-capsular surface antigens are now approved in the US, Europe, Australia and Canada.

2. Antimicrobial peptides

Antimicrobial peptides play an important role in host defense against microbial infection. In addition to being major components of the innate immune response, AMPs also have many potential roles in inflammatory responses by inducing the secretion of chemokines and cytokines [6]. Antimicrobial peptides are peptides of 12–50 amino acids with excess of basic amino acids (arginine, lysine and histidine), thus resulting in a net positive charge (cationic). AMPs also generally have significant portion of hydrophobic amino acids residues and are amphipathic to facilitate interaction with bacterial membranes. Based on their structural characteristics, AMPs are classified into different categories [7]. The most common classes are β-sheet peptides stabilized by disulfide bonds such as β-defensins [8, 9], and amphipathic α-helices formed upon contact with membranes such as α-defensins, cathelicidin and LL-37 [10-12]. Less common are extended peptides with a predominance of one or two amino acids (e.g. proline, tryptophan or histidine) and peptides with loop structures formed by either a single disulfide bond such as bactenecins. A cyclic lipopeptide, polymyxin B (PMB), has long been used as a model compound to define the mechanisms by which AMPs kill bacteria and how bacteria develop resistance to antimicrobial actions of AMPs.

The initial electrostatic interaction of the positively charged AMPs with the negatively charged lipopolysaccharides of the outer leaflet of the outer membrane is believed to initiate the self-promoted uptake of AMPs in Gram-negative bacteria [13]. Subsequently, both electrostatic and hydrophobic interactions between AMPs and the inner membrane
phospholipids are critical for AMP’s antimicrobial activity that disrupts membrane integrity. As the membrane-peptide complexes are insoluble and non-crystalline, solid-state NMR studies of AMPs [14] have been used to obtain structure, dynamics, orientation, and oligomeric states of AMPs in a membrane environment [15, 16] as well in lipopolysaccharide micelles [17-20]. These biochemical studies provide important information about the mechanism of action of AMPs at molecular level. Further, recent studies suggested that AMPs are also able to act on intracellular targets following their translocation across the inner membrane either as a main mode of action or as additive effects combining with membrane disruption [13, 21]. Expression of AMPs is widespread in many cell types. AMPs are constitutively produced by phagocytic cells such as macrophages and neutrophils [6]. For example, defensins have been shown to be the most abundant protein species in neutrophils [22]. Mucosal epithelial cells also constitutively expressed AMPs and AMP production can be further induced following exposure to bacterial determinants [23]. AMPs can also be formed by proteolytic digestion of larger cationic proteins such as lactoferricin, a proteolytic cleaved product from the N-terminus of lactoferrin [24].

3. AMP resistance mechanisms in *N. meningitidis*

Following acquisition through close contact with a carrier, meningococci overcome clearance and other local specific and nonspecific mucosal host defenses in order to colonize the upper respiratory mucosal surfaces (*e.g.*, the nasopharynx). Colonization of *N. meningitidis* may also result in invasion of epithelial surfaces, access to the bloodstream and the production of systemic and focal infections. As the only natural reservoir of *N. meningitidis* is the human nasopharynx, meningococci constantly encounter endogenous antimicrobial defense including antimicrobial peptides during colonization and infection. Thus, it is not surprising that meningococci have developed mechanisms for conferring intrinsic and/or inducible resistance to the action of AMPs. AMP resistance mechanisms have been well-characterized in various Gram negative bacteria to include (i) efflux pumps that export AMP from the periplasmic and intracellular compartments [25]; (ii) structural modifications of lipopolysaccharide (LPS) and lipooligosaccharide (LOS) to reduce interaction with AMPs; (iii) modulation of outer membrane permeability to limit entry and/or enhance excretion of AMPs; and (iv) proteases that degrade AMPs [26, 27]. Here we summarize the current knowledge of AMP resistance mechanisms as well as other characteristics that influence AMP resistance in *N. meningitidis* (Figure 1) in the order of importance. The inducible effects of AMPs on some of these resistance determinants will also be discussed.

3.1 Lipooligosaccharide (LOS)

Lipopolysaccharide (LPS) is the major component of the outer leaflet of the outer membrane of Gram-negative bacteria. Meningococcal LPS is a lipooligosaccharide (LOS) that is structurally similar to LPS, but does not have repeating O-antigens. Both LOS and LPS have a conserved inner core region composed of heptose and 3-deoxy-D-manno-2-octulosonic acid (KDO) attached to a lipid A moiety. The meningococcal lipid A structure has a symmetrical distribution of acyl chain (C12 and C14) attachments to the di-galactosamine.
backbone (Figure 1) and thus differs from that described for *E. coli* with an asymmetrical distribution of C14 and C16 acyl chains [28]. One of the best-characterized mechanisms of AMP resistance is remodeling of LPS [29]. It is believed that AMPs interacts with phosphorylated head groups of lipid A, and modification of the lipid A head groups correlates with increased PMB resistance. Such structural modifications that have been shown to affect CAMP resistance include i) removal of the phosphate head groups of the lipid A disaccharides [30, 31]; (ii) modifications of lipid A head groups by the addition of positively charged moieties, such as aminoarabinose [32-35], glucosamine [36], galactosamine [37] or phosphoethanolamine (PEA) [38, 39]; and (iii) alteration in the degree of lipid A acylation such as the formation of hepta-acylated lipid A [40, 41].

Among the different structural modifications of the lipid A head group identified in Gram negative bacteria, only the PEA modification has been demonstrated in *N. meningitidis*. This is consistent with the fact that meningococci only encodes the PEA transferase LptA [42] and the gene cassette encoding the aminoarabinose modification machinery is absent in the meningococcal genomes. In contrast to the lipid A of *E. coli* and *Salmonella enterica*, which may be modified by PEA after induction by certain environmental conditions [38], meningococcal lipid A is constitutively substituted with PEA [43, 44], which is a key factor that defines the intrinsic high level resistance of meningococci to PMB [39]. An *lptA* mutation caused ~ 250 fold reduction in PMB resistance to reach levels similar to those of *E. coli*. In comparison, an *mtr* mutation that inactivates major efflux pumps in meningococci resulted in a 16-fold reduction [39], demonstrating the LptA-mediated PEA decorations of lipid A is vital to meningococcal resistance. Recently, a poly-T₈ tract in the *lptA* coding sequence was shown to phase vary at a frequency of ~10⁻⁵ in *N. gonorrhoeae*, and the frame shift resulted in truncated LptA and PMB sensitivity [45]. Such a poly-T₈ tract is also present in meningococcal *lptA*, but it is as yet unknown whether it varies at a significant frequency. LptA is anchored to the periplasmic face of the cytoplasmic membrane by a transmembrane domain and utilizes the phosphatidylethanolamine lipid as its substrate. The crystal structure of LptA soluble domain was solved and shown to contain 5 disulfide bonds [46], suggesting that LptA is stabilized by disulfide bonds. Indeed, the presence of DsbA3, one of three DsbA proteins encoded in meningococci, supported LptA stability because lacking DsbA3 had a measurable decrease in the amount of PEA decoration on lipid A head groups [47]. Further, combinations of multiple *dsbA* mutations displayed an additive increase in sensitivity to PMB, indicating that all three oxidoreductases were needed for either LptA-dependent and/or independent pathways that lead to PMB resistance [47]. The constitutive modifications aiming to reduce negative charges in the LPS molecules appear to be a major determinant of antimicrobial peptide resistance in several high AMP resistant bacteria. In addition to *N. meningitidis* that utilizes constitutive PEA modification, *Burkholderia* sp. also constitutively produce LPS with aminoarabinose substitution [48] and is resistant to AMPs at a level similar to meningococci.

Additional structural features of lipid A contributing to PMB resistance have been characterized. While O-antigens [49] and inner core of LPS in *Burkholderia cenocepacia* [50] contribute to PMB resistance, further truncation of the outer or inner core oligosaccharides in meningococcal LOS, however, did not affect PMB susceptibility. An
outer membrane localized acyltransferase PagP, which transfers palmitate from phospholipid to lipid A to generate heptaacylated lipid A, is important for inducible AMP resistance in *Salmonella* and *E. coli* [40, 51], indicating that increasing lipid A acylation is an AMP resistance mechanism [39]. Varying lipid A acylation patterns in LPS could result in different outer membrane permeability and is a probable underlying AMP resistance mechanism. Although this hepta-acylation mechanism is absent in *N. meningitidis*, decreased acylation of lipid A indeed reduced AMP resistance, correlating with the effect of varying degrees of lipid A acylation on AMP resistance. Mutations in the late acyl transferases, *lpxL1* or *lpxL2*, responsible for adding the acyloxyacyl laurate chains to the 2 and 2’ positions of lipid A [52], resulted in penta-acylated lipid A and reduced PMB resistance [39]. Naturally occurring *lpxL1* mutations via different insertion/deletion events have been identified in many invasive meningococcal clinical isolates [53]. The resulting underacylated lipid A was shown to have low endotoxin activity with reduced proinflammatory cytokine induction [53]. Such variants, although become less resistant to AMPs, likely cause reduced AMP production, thus aiding meningococci to evade the innate immune system.

Finally, mutation in the ABC transporter system (*lptH*) responsible for LOS export [54] was also identified in a transposon mutagenesis study to further reduce AMP resistance [39]. A *lptH* mutant contained significantly lower cellular levels of LOS and released high levels of proteins into the medium [54]. The apparent leakiness of the *lptH* mutant, as indicated by their enhanced sensitivity toward vancomycin [54], likely allows AMP to reach its target membrane more readily, leading to higher PMB sensitivity.

### 3.2 Efflux pumps

Several efflux pumps including FarA/B [55], MacA/B [56], NorM [57] and MtrC/D/E [58], have been largely characterized in *N. gonorrhoeae* to mediate resistance toward various antimicrobial agents and meningococci encode orthologs of these gonococcal systems [59]. The Mtr pump is formed by the outer membrane MtrE, the membrane fusion protein MtrC and the inner membrane protein MtrD and belongs to the resistance-nodulation-division (RND) efflux pump family. Only the Mtr pump was shown to modulate gonococcal susceptibility to several structurally unrelated AMPs, such as the β-sheet peptide PG-1 and the α-helical peptide LL-37 [60]. However, human defensin HNP-2 is not a substrate of the gonococcal Mtr pump as an *mtr* mutant is equally resistance to this AMP [60]. The contribution of Mtr efflux pumps to AMP resistance in *N. meningitidis* has been clearly demonstrated as we have shown that the meningococcal Mtr pump decreases susceptibility to PMB, LL-37, and PG-1 [39]. In a transposon random mutagenesis screen, more than half of the PMB sensitive mutants are due to various insertions within the *mtrCDE* operon, supporting the importance of Mtr pump in AMP resistance [39]. These mutants displayed ~16-fold reduction in PMB resistance.

Meningococci, in general, exhibit ~ 5-fold higher PMB resistance compared to gonococci, partially due to genetic polymorphisms of the *mtr* locus between the two species. In *N. gonorrhoeae* the Mtr efflux pump is regulated by a divergently transcribed repressor, MtrR, and is inducible by its substrates through a transcriptional activator, MtrA [61] that is not
universally present in all gonococcal strains. However, in *N. meningitidis*, the Mtr pump is not inducible and is highly expressed due to various mutations in the *mtrR* coding sequence [62]. In addition, there are polymorphisms within the meningococcal *mtr* promoter region, including an insertion of a ~150-bp Correia element or an IS1301 element together with the Correia element. These genetic variations within the promoter region showed different promoter activities [62] that lead to varied Mtr pump expression levels.

### 3.3 Outer membrane proteins

As restricting access of AMPs to its cytoplasmic membrane targets confers resistance, one logical strategy in Gram negative bacteria is to reduce outer membrane permeability. In addition to LPS/LOS mediated outer membrane permeability changes described above, outer membrane porins may function as entry/excretion channels for AMPs and thus influence the levels of AMP crossing the outer membrane barrier. Indeed, PorB, one of the two major porins of *N. meningitidis*, affects AMP resistance because a *porB* mutant is 16-fold more sensitive to PMB [39]. This phenotype differs from the observation that a *porB* mutation increased resistances to several antibiotics such as ciprofloxacin and cephalosporins [63]. Since the *porB* mutant is not more susceptible to other Mtr efflux pump substrates, the increased PMB sensitivity was not caused by a decrease in the efflux function or levels of the Mtr pump. A general outer membrane permeability increase in the absence of PorB is also not likely as this would correlate with an increase in antibiotic sensitivity. Thus, the increased AMP sensitivity of the *porB* mutant suggests that excretion of AMPs by PorB is possibly an active AMP resistance mechanism.

On the other hand, the pilin secretion apparatus may act as an entry point for AMPs. A transposon screening for enhanced PMB resistance in *N. meningitidis* identified five mutants that all mapped in the *pilMNOPQ* locus [39], predicted to encode proteins involved in type IV pilus biogenesis. A mutant form of the pilus secretin protein PilQ in *N. gonorrhoeae* that allows increased entry of antimicrobial compounds has also been identified [64].

Outer membrane proteins may also play a role in sequestering AMP from reaching its targets. Two such examples have been characterized in *N. meningitidis*. First, fHBP-deficient strains are more sensitive to killing by LL-37 [65]. Factor H-binding protein (fHBP), an outer membrane lipoprotein, enables innate immune system evasion of *N. meningitidis* by binding to the inhibitor of the complement alternative pathway, factor H, and is one of the recombinant vaccine antigens present in serogroup B meningococcal vaccine [66]. The fHBP protein does not have proteolytic activity against LL-37, does not affect efflux of LL-37 and no decreased outer membrane stability is detected in the mutant [65]. As the mutant is more resistant to killing by LL-37 in the presence of 2% NaCl and low pH, it was suggested that fHBP likely mediate electrostatic interaction with LL-37 as a sequestration mechanism to prevent contact with the cell membrane. Second, lactoferrin binding protein B (LbpB), a surface-exposed membrane bound lipoprotein, was shown to provide protection against lactoferricin [67] and the cathelicidin related antimicrobial peptide (mCRAMP), but not against LL37 [68]. LbpB works together with LbpA to constitute host-specific lactoferrin receptors and can be selectively released from the
bacterial surface [69]. The negatively charged amino acid clusters of LbpB are responsible for the protective effect against lactoferricin [67].

3.4 Capsular polysaccharides

*N. meningitidis* is encapsulated and expresses one of the 12 capsular polysaccharide (CPS) structures (e.g. serogroup). Capsule is the most critical meningococcal virulence determinant during bacteremia, meningitis and other invasive meningococcal disease, as it imparts antiphagocytic and antibactericidal properties to the meningococcus [43, 70-72]. An additional mechanism by which the capsule protects meningococci is to provide increased resistance to AMPs as unencapsulated serogroup B (α-2, 8-polysialic acid capsule) strains were more susceptible than encapsulated meningococci to defensins (β defensing 1&2, HNP-1&2) cathelicidins (LL-37, CRAMP, CRAMP-18), protegrin PG-1, and polymyxin B [73]. Similarly, a contribution from capsule to LL-37 resistance was shown in an encapsulated serogroup C strain that expresses α-2, 9-polysialic acid capsule [74]. Further, this study showed that after exposure to nonlethal concentrations of LL-37, higher proportion of unencapsulated meningococci accumulated LL-37 on the surface compared to the encapsulated wild-type strain [74], suggesting that CPS reduces the binding of LL-37 to the bacterial surface. All disease-causing meningococcal serogroups express negatively charged capsular polysaccharides and the nonproductive electrostatic interaction between CPS and AMP could serve as a sequestering mechanism to limit AMP reaching its targets. Thus, CPS acts as a shield to reduce the binding of AMPs to bacterial surface. As a correlation, CPS-mediated AMP resistance in *Klebsiella pneumoniae* was shown to be unrelated to the CPS chemical composition but was dependent on the amount of CPS expressed [75].

3.5 Bleb and biofilm

Meningococci are characterized by frequent vesiculation (blebing) of the outer membrane [76] that appears to contribute to rapid initiation of the inflammatory cascades of meningococcal diseases. Blebs, which contain DNA, outer membrane proteins and LOS, have been shown to be major constituents of the biofilm matrix and the ability to produce blebs shown to be crucial to biofilm formation in *N. gonorrhoeae* [77]. Contributions of biofilm to AMP resistance have been characterized in other bacteria [78] and likely also play a role in meningococcal AMP resistance. *N. meningitidis* has been shown to form biofilm on abiotic surfaces as well as on epithelial cells [79-81]. Blebbing may potentially function as another sequestering mechanism of AMP evasion through the unproductive electrostatic interactions between LOS/DNA within blebs and AMPs, either in the presence or absence of biofilm.

4. Response to AMP exposure in *N. meningitidis*

Without constitutive and intrinsically high levels of resistance, bacteria targeted by AMPs have to be able to detect and respond to AMPs and the efficiency of these processes are important for the survival of bacteria in the host [82]. Well-characterized response mechanisms are the PhoP/PhoQ and PmrA/PmrB two-component system-mediated inducible resistance to AMPs that resulted in modifications of lipid A head groups by
aminoarabinose and PEA and formation of hepta-acylated lipid A [83, 84]. The fact that both PEA modification of the LOS lipid A head groups and the Mtr efflux pump were constitutively expressed at high levels likely reduces the dependence on inducible AMP resistance in \textit{N. meningitidis}. However, inducible responses to AMP exposure in \textit{N. meningitidis} have been shown in several studies. A mutation in the MisR/MisS two-component system caused a 2-fold reduction in \textit{lptA} expression [44]. Although no quantitative changes in PEA modification levels of lipid A were detected, the \textit{misR/misS} mutants are more sensitive to PMB, suggesting that other genes controlled by this two-component system are involved in AMP resistance. Exposures to PG-1 and LL-37 at concentrations close to the MIC elicit an increase (~1.5-2 fold) on \textit{mtrCDE} transcript levels in \textit{N. meningitidis} [73]. As these two AMPs are not structurally related, the up-regulation is unlikely promoted by sensing specific AMPs, but potentially by sensing perturbation of the inner and/or outer membrane. Another study showed an up-regulation of \textit{mtrD} upon a 30 minute exposure to sublethal dose of LL-37 [74]. Interestingly, exposure to LL-37 also further induces expression of CPS genes in this study [74]. A global transcriptome study performed by treating a serogroup B meningococcal strain with a sublethal concentration of CRAMP, a mouse LL-37 homolog, for 1 hour found a total of 21 genes being differentially expressed greater than 2-fold [85]. Up-regulated genes encode proteins involved cell envelope processing such as pilin glycosylation; while genes involved in energy metabolism are down-regulated. Among many affected genes with unknown functions [85], two encoding conserved hypothetical proteins were further characterized. A mutation in either NMB0741 or NMB1828 caused ~3-log lower bacteremia in an adult mouse model of infection and the NMB1828 protein binds LL-37 \textit{in vitro} [85].

5. Summary

Considerable progress has been made in identification of the molecular basis of antimicrobial peptide resistance mechanisms in \textit{N. meningitidis} and many other bacterial pathogens. Resistance to antimicrobial peptides is multifactorial as pathogens use multiple mechanisms to resist AMPs. The contribution and the relative importance of each resistance mechanism vary in different bacterial species. \textit{N. meningitidis} utilizes several efficient strategies to defend against AMPs. The critical mechanism is constitutive LOS modification by PEA, which is further enhanced by efficient excretion of AMPs by efflux pumps. Other resistance mechanisms, such as CPS and outer membrane protein expression, appear to play a more limited role but contribute to the total high level of resistance. As AMPs are actively being explored as a new class of antimicrobial therapeutics [86, 87], expanding our understanding of AMP resistance mechanisms in bacterial pathogens is essential.

Acknowledgement

This work was supported in part by NIH Grant 5R01 AI40247 awarded to DSS and by NIH Grant R56AI 061031 awarded to YT.

References


Highlights

• *N. meningitidis* is highly resistant to antimicrobial peptides (AMPs)
• Meningococcal AMP resistance mechanisms are summarized.
• Constitutive modification of lipid A by phosphoethanolamine is most critical.
• AMP excretion by efflux pumps contributes to meningococcal AMP resistance.
Figure 1.
A schematic summary of cellular factors influencing antimicrobial peptide resistance in *Neisseria meningitidis*. AMPs can initiate the self-promoted uptake through electrostatic interactions with negatively charged lipopolysaccharides of the outer membrane or through the secretin apparatus of type IV pili. The constitutive PEA modification of lipid A head groups reduces electrostatic interactions of AMPs with the cell envelop, while both capsule and bleb act to sequester AMPs from reaching the cell surface. The Mtr efflux pump can expel AMPs from either periplasm or cytoplasm by active efflux, and the major outer membrane porin, PorB, also likely functions as an excretion channel.